MétaCan
Menu
Back to cohort
Record W4412426553 · doi:10.1093/jbmrpl/ziaf119

Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density

2025· article· en· W4412426553 on OpenAlexaff
Timo Damm, Cesar Libanati, Jaime Peña, David A. Hanley, Michael A. Bolognese, Christopher Recknor, Claus‐Christian Glüer

Bibliographic record

VenueJBMR Plus · 2025
Typearticle
Languageen
FieldMedicine
TopicCytokine Signaling Pathways and Interactions
Canadian institutionsUniversity of Calgary
FundersEli Lilly and CompanyAmgen
KeywordsTeriparatideMedicineSclerostinCortical boneCancellous boneOsteoporosisBone mineralFemoral neckBone densityQuantitative computed tomographyPlaceboInternal medicineUrologyEndocrinologyAnatomyChemistryPathology

Abstract

fetched live from OpenAlex

Abstract Romosozumab, a sclerostin inhibitor, exerts a dual effect of increasing bone formation while decreasing bone resorption to rapidly increase bone mineral density (BMD) and reduce fracture risk in postmenopausal women. Iterative Convolution OptimizatioN (ICON) allows accurate calculation of deconvolved cortical thickness from high-resolution quantitative computed tomography (HR-QCT) scanning. This study employed HR-QCT to evaluate compartmental (including endosteal and periosteal) changes in the vertebral cortical shell in postmenopausal women who received romosozumab, teriparatide, or placebo. In a subset of a phase 2, randomized study (NCT00896532), women (55-85 yr) with low BMD (T-score ≤ −2.0, but not <−3.5, at the lumbar spine, total hip, or femoral neck) treated with subcutaneous (SC) romosozumab monthly (210 mg; n = 11), SC teriparatide daily (20 μg; n = 12), or SC placebo (n = 8) had spine HR-QCT scans at baseline and Month 12 to assess treatment effects on cortical and cancellous compartments of the T12 vertebra. HR-QCT was obtained at 120 kVp and 360 mAs. Cortical changes were evaluated using ICON software. At Month 12, compared to teriparatide and placebo, romosozumab treatment was associated with greater gains in all cortical parameters. Changes in cancellous bone parameters were similar with romosozumab and teriparatide. Romosozumab significantly increased cortical thickness (mean ± SD; 53 ± 18%) and the magnitude of this change was greater than that of teriparatide (20 ± 13%) and placebo (3 ± 6%); all p < .001. With romosozumab, cortical BMC and apparent cortical BMD were also significantly increased from baseline, and compared to teriparatide and placebo (all p < .001). These changes occurred through endosteal and periosteal bone matrix apposition, with greatest changes seen at the endosteal surface. The location and magnitude of these changes likely form the basis of the rapid improvement in bone mass, structure, and strength that contribute to romosozumab’s rapid vertebral fracture risk reduction efficacy; however, conclusions are limited by the small sample size.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.275
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJBMR PlusSame topicCytokine Signaling Pathways and InteractionsFrench-language works237,207